The discovery of microRNAs (miRNAs) is one of the most significant breakthroughs in recent decades. miRNAs are a class of small, endogenous, non-coding RNAs (19-24 nt) that negatively regulate the expression of target genes by binding to their 39 untranslated region and are involved in various biological processes. Three main approaches that are globally used for the detection of miRNA include direct cloning, forward genetics and computational approaches using bioinformatics. 1 The bioinformatic approach uses the available transcriptomic and genomic data for mining miRNAs using a homology search with the existing miRNAs. In the current study, a computational approach was employed to identify potent miRNAs involved in the inflammatory response of the liver. The rat model of lipopolysaccharide (LPS)-induced liver inflammation was used, and the expression of the candidate miRNAs in hepatocytes was quantified by real-time polymerase chain reaction (qRT-PCR).
Inflammation is the first step toward combating antigens and toward tissue recovery, and in some instances, it proceeds to a chronic state associated with debilitating autoimmune diseases, such as multiple sclerosis or even cancer. Chronic inflammation of liver tissues may lead to fibrosis, steatosis and cirrhosis, and may end with cancer. The response of liver tissue to chronic injury is stimulated by pro-inflammatory factors, such as bacterial endotoxin or interleukin-1. 2 There is an increasing paradigm that miRNAs regulate different biological processes in various cell types within the liver, including liver pathology and cancer. 3 The expression of MiR-517a, miR-892a and miR-106a* in bile was increased in patients with Ischemic type biliary lesions, a biliary complication encountered after liver transplantation. 4 Although several miRNAs have been reported, miR-155, miR-146a and miR-125b are considered potent miRNAs involved in inflammation-mediated hepatocyte damage at multiple levels by targeting a pro-inflammatory cytokine production cascade where Toll-like receptor and intracellular signaling pathways determine pro-and antiinflammatory cytokines. 5 An increasing body of evidence has clearly shown that a differential expression of miRNAs is associated with liver diseases, such as hepatitis C and hepatitis B, metabolic disorders and drug abuse. 6 Different approaches have been used to identify novel miRNAs that are involved in liver disorders. In our study, we used a computational approach that enabled us to identify two inflammatory responsive liver miRNAs from 89 liver EST sequences: rno-miR-24 and rno-miR-466i-5p. In the current study, the MiRBase database was used to identify miRNAs and their conserved homologues from liver ESTs under inflammatory conditions. In brief, the EST sequences (89, February 2013) of hepatic transcripts preferentially expressed during acute inflammation were downloaded from the NCBI database (http://www.ncbi.nlm.nih.gov/nuccore) by searching 'liver inflammation', and the inflammatory-responsive miRNAs were predicted as described by Thirugnanasambantham et al. 1 The careful analysis of 89 liver EST sequences revealed 10 non-protein-encoding ESTs homologous to the miRNA sequences. A secondary structural analysis of the pre-miRNA-related sequence from the 10 non-coding ESTs revealed the presence of 2 miRNA encoding transcripts in the liver inflammatory EST sequences (Figure 1a and b) . The source of the sequences, length of the precursor sequences and their minimum folding free energies and A1U content for the predicated miRNAs are shown in Figure 1c . Among the predicted miRNAs from the analyzed liver ESTs, rno-miR-24 was observed in the indirect strand and rno-miR-466i-5p was observed in the direct strand. rno-miR-466i-5p and rno-miR-24 had a minimum free energy of 229.74 and 248.1 kcal/mol, respectively, with an average of 238.92 kcal/mol. While considering the A1U percentage in the predicted miRNAs, it was approximately 50% and 47.4% in rnomiR-466i-5p and rno-miR-24, respectively.
To further confirm the expression of the identified miRNAs in response to inflammation in liver cells, the hepatocytes were isolated from rat livers by the collagenase perfusion method, and inflammation was induced with LPS (1 mg/ml; SigmaAldrich, St Louis, MO, USA). Total RNA was extracted for the quantitative determination of COX-2, iNOS and the housekeeping gene GAPDH using real-time PCR analysis from stimulated and unstimulated cells at 4, 8, 12, 24, 36 and 48 h after LPS challenge. The forward and reverse primers used for inflammatory marker gene expressions were as follows: iNOS forward: 59-ACAACAGGAACCTACCAGCTCA-39, reverse: 59-GATGTTGTAGCGCTGTGTGTCA-3; COX-2 forward: 59-TG-TATGCTACCATCTGGCTTCGG-39, reverse: 59-GTTTGGAAC AGTCGCTCGTCATC-39, and GAPDH forward: 59-GTATTG-G GCGCCTGGTCACC-39, reverse: 59-CGCTCCTGGAAGAT-GGTGATGG-39). The cycling condition was 35 cycles of 94 uC for 30 s, 60 uC for 45 s and 72 uC for 1 min followed by a final extension step at 72 uC for 7 min. Reverse transcription and quantitative expression analyses of rno-miR-24, rno-miR-466i-5p, and the endogenous control U6 were performed using realtime PCR as described previously. 8 The primer sequences used for stem-loop RT-PCR were as follow: rno-miR-24 stem loop RT primer 59-GTCGTATCCAGTGCAGGGTCCGAGGTATT-CGCACTGGATACGACCTTCTG-39; forward primer 59-GCG-GCGGTGGCTCAGTACAGC-39; rno-miR-466i-5p stem loop RT primer 59-GTCGTATCCAGTGCAGGGTCCGAGGTATT-CGCACTGGATACGACCACACA-39; forward primer 59-GCG-GCGGTGTGTGTGTGTGTG-39; Universal reverse primer 59-GTGCAGGGTCCGAGGT-39; U6 RT primer 59-AACGCTTCA-CGAATTTGCGTG-39; U6 forward primer 59-GCTCGCTTCG-GCAGCACA-39; U6 reverse primer 59-GAGGTATTCGCACC-AGAGGA-39. The relative expression of target genes was stated as a fold ratio using the (DDC T check) 2 2DDC T method. The expression patterns of the genes encoding inflammatory markers ( Figure 1d ) and identified miRNAs ( Figure 1e ) were analyzed in control and LPS-stimulated hepatocytes using realtime PCR. The expression of mRNA encoding COX-2 and iNOS were upregulated in proportion with LPS stimulation up to 24 h. We observed that the inflammatory markers COX-2 and iNOS reached the maximum level at 24 h (6.33-and 5.09-fold, respectively) and started to decline from 36 h (4.14-and 4.94-expression fold, respectively) after LPS treatment. However, the expression of both miRNAs was detected from 12 h after LPS treatment, in parallel with inflammation progression, as denoted by the expression of inflammatory markers. The maximum expression of both miR-24 and miR-466i-5p was reached 72 h (5.38 and 4.48 expression fold, respectively) after LPS treatment.
In in vitro studies, increases in mRNA expression of COX-2 and iNOS levels upon LPS stimulation of hepatocytes were observed in this study. A similar expression pattern of iNOS was noticed from earlier studies in liver slices, where the expression was observed after 5 h of incubation with LPS and increased until 24 h. 9 We found that the expression levels of both miRNAs were upregulated with LPS treatment. A similar result was observed with miR-155, a regulator of inflammation. 5 Simultaneously, as denoted by the expression of inflammatory markers (COX-2 and iNOS), the inflammation was suppressed with the increase in expression of rno-miR-24 and rno-miR-466i-5p. Song et al. 10 reported the upregulation of miR-466i in SST-treated chronic liver disease. In conclusion, our data identify two new miRNAs, miR-24 and miR-466i, which are upregulated in hepatocytes in response to inflammatory stimuli. This upregulation was reciprocally related with the inflammatory markers COX-2 and iNOS, suggesting that they are target genes in liver inflammation. The anti-inflammatory miRNAs identified with a computational approach are known to be involved in the regulation of inflammatory reactions. Furthermore, the analysis of inflammatory markers revealed that the level of inflammation was reduced with an increase in the expression level of the identified miRNA. Therefore, data from this study may open intriguing possibilities for the therapeutic value of the identified miRNAs as antiinflammatory factors for liver injury.
